Celexa — Competitive Intelligence Brief

Celexa (CITALOPRAM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin Reuptake Inhibitor. Area: Neuroscience.

marketed Serotonin Reuptake Inhibitor Sodium-dependent serotonin transporter Neuroscience Small molecule

Target snapshot

Celexa (CITALOPRAM) — AbbVie. Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Celexa TARGET	CITALOPRAM	AbbVie	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Fetzima	LEVOMILNACIPRAN	AbbVie	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2013-01-01
Pristiq	desvenlafaxine	Alembic Pharms Ltd	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2008-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Racemic Sibutramine	SIBUTRAMINE		marketed	Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic	Sodium-dependent serotonin transporter	1997-01-01
Serzone	NEFAZODONE	Bristol-Myers Squibb	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1994-01-01
Luvox	FLUVOXAMINE		marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin Reuptake Inhibitor class)

1. · 1 drug in this class
2. AbbVie · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class